Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5090793 | 0.86 | TSHR (0.61) | MAPTLMNAPOLBNPSR1PLA2G4B | |
| SCHEMBL6322342 | 0.86 | TSHR (0.61) | MAPTLMNAPOLBNPSR1PLA2G4B | |
| SCHEMBL588999 | 0.85 | ABCB1 (0.63) | LMNAPLA2G4BABCB1S1PR1TP53 | |
| SCHEMBL588614 | 0.85 | ABCB1 (0.63) | LMNAPLA2G4BABCB1S1PR1TP53 | |
| SCHEMBL27870163 | 0.85 | ABCB1 (0.63) | LMNAPLA2G4BABCB1S1PR1TP53 | |
| SCHEMBL6836270 | 0.85 | ABCB1 (0.63) | LMNAPLA2G4BABCB1S1PR1TP53 | |
| SCHEMBL258672 | 0.85 | ABCB1 (0.63) | LMNAPLA2G4BABCB1S1PR1TP53 | |
| SCHEMBL8496739 | 0.84 | MAPT (0.55) | MAPTLMNAPOLBNPSR1PLA2G4B | |
| SCHEMBL9416946 | 0.84 | MAPT (0.55) | MAPTLMNAPOLBNPSR1PLA2G4B | |
| SCHEMBL11203428 | 0.83 | ABCB1 (0.64) | MAPTLMNAPOLBNPSR1PLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060173058-A1 | Kcnq channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173058-A1 | Kcnq channel modulating compounds and their pharmaceutical use | KCNQ1, KCNQ2, KCNQ5 | MAPT 2020/4885LMNA 1651/4885POLB 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.